切换至 "中华医学电子期刊资源库"

中华实验和临床感染病杂志(电子版) ›› 2023, Vol. 17 ›› Issue (03) : 145 -150. doi: 10.3877/cma.j.issn.1674-1358.2023.03.001

综述

胃癌的高危可控因素——幽门螺杆菌感染
李梦声, 韩中博()   
  1. 261053 潍坊市,潍坊医学院临床医学院
    255036 淄博市,淄博市中心医院胃肠外科
  • 收稿日期:2023-03-06 出版日期:2023-06-15
  • 通信作者: 韩中博
  • 基金资助:
    山东省医药卫生科技发展计划项目(No. WS2019305)

High risk and controllable factor of gastric cancer--Helicobacter pylori infection

Mengsheng Li, Zhongbo Han()   

  1. School of Clinical Medicine, Weifang Medical University, Weifang 261053, China
    Department of Gastrointestinal Surgery, Zibo Central Hospital, Zibo 255036, China
  • Received:2023-03-06 Published:2023-06-15
  • Corresponding author: Zhongbo Han
引用本文:

李梦声, 韩中博. 胃癌的高危可控因素——幽门螺杆菌感染[J/OL]. 中华实验和临床感染病杂志(电子版), 2023, 17(03): 145-150.

Mengsheng Li, Zhongbo Han. High risk and controllable factor of gastric cancer--Helicobacter pylori infection[J/OL]. Chinese Journal of Experimental and Clinical Infectious Diseases(Electronic Edition), 2023, 17(03): 145-150.

幽门螺杆菌感染是消化道溃疡、胃癌以及其他胃疾病的主要致病因素。全球约50%人口受到感染,且存在明显的地区差异。感染主要是经口-口或粪-口途径,病原体可通过改变胃内环境、介导免疫和产生毒力因子,从而成功定植于强酸环境中并发挥致病作用。尽管大多数幽门螺杆菌阳性患者无明显症状,但感染会导致各种胃肠道疾病的发展,致使胃腺癌的发病率进而升高。抗菌药物和铋剂治疗方案在幽门螺杆菌根治中发挥至关重要的作用,但其耐药率高居不下一直为临床治疗中的巨大挑战,这也间接促进了益生菌疗法和相关疫苗研发的进展。由于流行病学条件的变化、具有治疗意义的耐药模式变化以及病原体根治适应证的更新,幽门螺杆菌的医学管理是一个需要定期重新评估的动态过程。本文概述了幽门螺杆菌感染研究现状、致癌机制和治疗方案,重点强调具有高致病性的细菌毒力因子(以cagA和vacA为主)通过可能存在的机制,影响上皮细胞增殖和凋亡间的平衡从而导致癌症发生,旨在提升对幽门螺杆菌感染的认知和防治水平。

Helicobacter pylori (H. pylori) infection is the main pathogenic factor of peptic ulcer, gastric cancer and other gastric diseases. About 50% people worldwide were infected, with significant regional differences. H. pylori infection mainly through oral-oral or fecal-oral route. Pathogens can successfully colonize in strong acid environment and play a pathogenic role in changing the intragastric environment, mediating immunity and producing virulence factors. Although most H. pylori positive patients have no obvious symptoms, the infection will lead to the development of various gastrointestinal diseases, and increases of the incidence of gastric adenocarcinoma. Antibiotics and bismuth agents play a crucial role in the eradication of H. pylori, but the high drug resistance rate has been a great challenge in clinical treatment, which also indirectly promoted the development of probiotics therapy and related vaccines. Due to the change of epidemiological conditions, the change of drug resistance patterns with therapeutic significance and the update of the indications for radical treatment of pathogens, the medical management of H. pylori is a dynamic process that needs to be re-evaluated regularly. This article summarizes the research status, carcinogenic mechanism and treatment of H. pylori infection, and emphasizes the highly pathogenic bacterial virulence factors (mainly including cagA and vacA) affect the balance between epithelial cell proliferation and apoptosis through possible mechanisms which will lead to cancer, inorder to improve the understanding and prevention level of H. pylori infection.

表1 幽门螺杆菌根除指征
[1]
Ren S, Cai P, Liu Y, et al. Prevalence of Helicobacter pylori infection in China: A systematic review and meta-analysis[J]. J Gastroenterol Hepatol,2022,37(3):464-470.
[2]
Chiang TH, Chang WJ, Chen SL, et al. Mass eradication of Helicobacter pylori to reduce gastric cancer incidence and mortality: a long-term cohort study on Matsu Islands[J]. Gut,2021,70(2):243-250.
[3]
de Brito BB, Da SF, Soares AS, et al. Pathogenesis and clinical management of Helicobacter pylori gastric infection[J]. World J Gastroenterol,2019,25(37):5578-5589.
[4]
Marshall BJ, Warren JR. Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration[J]. Lancet, 1984,1(8390):1311-1315.
[5]
Sugano K, Tack J, Kuipers EJ, et al. Kyoto global consensus report on Helicobacter pylori gastritis[J]. Gut,2015,64(9):1353-1367.
[6]
Malfertheiner P, Megraud F, O’Morain CA, et al. Management of Helicobacter pylori infection-the Maastricht V/Florence Consensus Report[J]. Gut,2017,66(1):6-30.
[7]
Malnick SD, Melzer E, Attali M, et al. Helicobacter pylori: friend or foe?[J]. World J Gastroenterol,2014,20(27):8979-8985.
[8]
Hooi J, Lai WY, Ng WK, et al. Global prevalence of Helicobacter pylori infection: systematic review and Meta-analysis[J]. Gastroenterology, 2017,153(2):420-429.
[9]
Du LJ, Chen B R, Kim JJ, et al. Helicobacter pylori eradication therapy for functional dyspepsia: Systematic review and meta-analysis[J]. World J Gastroenterol,2016,22(12):3486-3495.
[10]
Sugano K. Effect of Helicobacter pylori eradication on the incidence of gastric cancer: a systematic review and meta-analysis[J]. Gastric Cancer,2019,22(3):435-445.
[11]
Uno Y. Prevention of gastric cancer by Helicobacter pylori eradication: A review from Japan[J]. Cancer Med,2019,8(8):3992-4000.
[12]
Yap TW, Leow AH, Azmi AN, et al. Global fecal and plasma metabolic dynamics related to Helicobacter pylori eradication[J]. Front Microbiol,2017,8:536.
[13]
Francois F, Roper J, Joseph N, et al. The effect of H. pylori eradication on meal-associated changes in plasma ghrelin and leptin[J]. BMC Gastroenterol,2011,11(1):37.
[14]
Koch KN, Hartung ML, Urban S, et al. Helicobacter urease-induced activation of the TLR2/NLRP3/IL-18 axis protects against asthma[J]. J Clin Invest,2015,125(8):3297-3302.
[15]
den Hollander WJ, Sonnenschein-van DVA, Holster IL, et al. Helicobacter pylori in children with asthmatic conditions at school age, and their mothers[J]. Aliment Pharmacol Ther,2016,43(8):933-943.
[16]
Harrison U, Fowora MA, Seriki AT, et al. Helicobacter pylori strains from a Nigerian cohort show divergent antibiotic resistance rates and a uniform pathogenicity profile[J]. PLoS One,2017,12(5):e176454.
[17]
Mahant S, Sharma AK, Gehlot V, et al. Geographically distinct North-East Indian Helicobacter pylori strains are highly sensitive to clarithromycin but are levofloxacin resistant[J]. Indian J Med Microbiol,2019,37(3):337-344.
[18]
Zhou L, Zhang J, Song Z, et al. Tailored versus triple plus bismuth or concomitant therapy as initial Helicobacter pylori treatment: A randomized trial[J]. Helicobacter,2016,21(2):91-99.
[19]
Alarcón T, Llorca L, Perez-Perez G. Impact of the microbiota and gastric disease development by Helicobacter pylori[J]. Curr Top Microbiol Immunol,2017,400:253-275.
[20]
Chen CC, Liou JM, Lee YC, et al. The interplay between Helicobacter pylori and gastrointestinal microbiota[J]. Gut Microbes,2021,13(1):1-22.
[21]
Llorca L, Pérez-Pérez G, Urruzuno P, et al. Characterization of the gastric microbiota in a pediatric population according to Helicobacter pylori status[J]. Pediatr Infect Dis J,2017,36(2):173-178.
[22]
Sung J, Coker OO, Chu E, et al. Gastric microbes associated with gastric inflammation, atrophy and intestinal metaplasia 1 year after Helicobacter pylori eradication[J]. Gut,2020,69(9):1572-1580.
[23]
Baj J, Forma A, Sitarz M, et al. Helicobacter pylori virulence factors-mechanisms of bacterial pathogenicity in the gastric microenvironment[J]. Cells,2020,10(1):27.
[24]
Ferreira RM, Pereira-Marques J, Pinto-Ribeiro I, et al. Gastric microbial community profiling reveals a dysbiotic cancer-associated microbiota[J]. Gut,2018,67(2):226-236.
[25]
Muzaheed. Helicobacter pylori oncogenicity: mechanism, prevention, and risk factors[J]. Sci World J,2020,2020:3018326.
[26]
Yang JY, Kim JB, Lee P, et al. Evodiamine inhibits Helicobacter pylori growth and Helicobacter pylori-induced inflammation[J]. Int J Mol Sci,2021,22(7):3385.
[27]
Yang H, Hu B. Immunological perspective: Helicobacter pylori infection and gastritis[J]. Mediators Inflamm,2022,2022:2944156.
[28]
Sukri A, Hanafiah A, Mohamad ZN, et al. Epidemiology and role of Helicobacter pylori virulence factors in gastric cancer carcinogenesis[J]. APMIS,2020,128(2):150-161.
[29]
Suarez G, Romero-Gallo J, Sierra JC, et al. Genetic manipulation of Helicobacter pylori virulence function by host carcinogenic phenotypes[J]. Cancer Res,2017,77(9):2401-2412.
[30]
Basso D, Zambon CF, Letley DP, et al. Clinical relevance of Helicobacter pylori cagA and vacA gene polymorphisms[J]. Gastroenterology, 2008,135(1):91-99.
[31]
Queiroz DM, Silva CI, Goncalves MH, et al. Higher frequency of cagA EPIYA-C phosphorylation sites in H. pylori strains from first-degree relatives of gastric cancer patients[J]. BMC Gastroenterol,2012,12:107.
[32]
Li M, Chen T, Wang R, et al. Plant MIR156 regulates intestinal growth in mammals by targeting the Wnt/β-catenin pathway[J]. Am J Physiol Cell Physiol,2019,317(3):C434-C448.
[33]
Mimuro H, Suzuki T, Tanaka J, et al. Grb2 is a key mediator of Helicobacter pylori CagA protein activities[J]. Mol Cell,2002,10(4):745-755.
[34]
Chauhan N, Tay A, Marshall BJ, et al. Helicobacter pylori VacA, a distinct toxin exerts diverse functionalities in numerous cells: An overview[J]. Helicobacter,2019,24(1):e12544.
[35]
Alipour M. Molecular Mechanism of Helicobacter pylori-Induced Gastric Cancer[J]. J Gastrointest Cancer, 2021,52(1):23-30.
[36]
Sallas ML, Dos SM, Orcini WA, et al. Status (on/off) of oipA gene: their associations with gastritis and gastric cancer and geographic origins[J]. Arch Microbiol,2019,201(1):93-97.
[37]
Alam J, Sarkar A, Karmakar BC, et al. Novel virulence factor dupA of Helicobacter pylori as an important risk determinant for disease manifestation: An overview[J]. World J Gastroenterol,2020,26(32):4739- 4752.
[38]
Ling SS, Khoo LH, Hwang LA, et al. Instrumental role of Helicobacter pylori γ-glutamyl transpeptidase in VacA-dependent vacuolation in gastric epithelial cells[J]. PLoS One,2015,10(6):e131460.
[39]
Kim SH, Lim JW, Kim H. Astaxanthin prevents decreases in superoxide dismutase 2 level and superoxide dismutase activity in Helicobacter pylori-infected gastric epithelial cells[J]. J Cancer Prev,2019,24(1):54-58.
[40]
Gonciarz W, Krupa A, Hinc K, et al. The effect of Helicobacter pylori infection and different H. pylori components on the proliferation and apoptosis of gastric epithelial cells and fibroblasts[J]. PLoS One,2019,14(8):e220636.
[41]
Vallejo-Flores G, Torres J, Sandoval-Montes C, et al. Helicobacter pylori CagA suppresses apoptosis through activation of AKT in a nontransformed epithelial cell model of glandular acini formation[J]. Biomed Res Int,2015,2015:761501.
[42]
Schmalstig AA, Benoit SL, Misra SK, et al. Noncatalytic antioxidant role for Helicobacter pylori urease[J]. J Bacteriol,2018,200(17):e00124-18.
[43]
Seo SI, Lim H, Bang CS, et al. Bismuth-based quadruple therapy versus metronidazole-intensified triple therapy as a first-line treatment for clarithromycin-resistant Helicobacter pylori infection: A multicenter randomized controlled trial[J]. Gut Liver,2022,16(5):697-705.
[44]
Yuan Z, Xiao S, Li S, et al. The impact of Helicobacter pylori infection, eradication therapy, and probiotics intervention on gastric microbiota in young adults[J]. Helicobacter,2021,26(6):e12848.
[45]
Zagari RM, Romiti A, Ierardi E, et al. The "three-in-one" formulation of bismuth quadruple therapy for Helicobacter pylori eradication with or without probiotics supplementation: Efficacy and safety in daily clinical practice[J]. Helicobacter,2018,23(4):e12502.
[46]
Zeng M, Mao XH, Li JX, et al. Efficacy, safety, and immunogenicity of an oral recombinant Helicobacter pylori vaccine in children in China: a randomised, double-blind, placebo-controlled, phase 3 trial[J]. Lancet, 2015,386(10002):1457-1464.
[1] 杨柳, 宋振川, 王新乐. 乳腺癌改良根治术联合背阔肌复位的临床疗效评估[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(05): 269-273.
[2] 崔玉峰, 林毅军, 王志民. 幽门螺杆菌分子检测技术研究进展[J/OL]. 中华实验和临床感染病杂志(电子版), 2024, 18(05): 257-262.
[3] 奚卫, 王闻卿, 刘玥, 王亚楠, 许学斌. 胃肠炎继发脓毒症感染创伤弧菌ST14514的病原学诊断与文献病例回顾分析[J/OL]. 中华实验和临床感染病杂志(电子版), 2024, 18(05): 293-302.
[4] 郭伟仪, 林沛玲. 不同抗体型幽门螺杆菌感染与溃疡性结肠炎患者疾病活动及组织学评分的关系[J/OL]. 中华实验和临床感染病杂志(电子版), 2024, 18(04): 237-244.
[5] 李刘庆, 陈小翔, 吕成余. 全腹腔镜与腹腔镜辅助远端胃癌根治术治疗进展期胃癌的近中期随访比较[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 23-26.
[6] 刘世君, 马杰, 师鲁静. 胃癌完整系膜切除术+标准D2根治术治疗进展期胃癌的近中期随访研究[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 27-30.
[7] 燕速, 霍博文. 腹腔镜食管胃结合部腺癌根治性切除术[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 13-13.
[8] 韩萌萌, 冯雪园, 马宁. 乳腺癌改良根治术后桡神经损伤1例[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 117-118.
[9] 黄一博, 李至彦, 林晨, 陶亮, 王萌, 管文贤. 胃癌根治术中淋巴结示踪剂的研究进展[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(05): 586-588.
[10] 刘虹, 王品, 王彬, 任杰超, 张文杰, 吴剑, 刘莹. 经腋窝腔镜辅助保留乳头乳晕皮下腺体切除术+Ⅰ期胸肌前假体乳房重建术[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(04): 419-422.
[11] 施一辉, 张平新, 朱勇, 杨德林. 机器人辅助前列腺根治术后切缘阳性的研究进展[J/OL]. 中华腔镜泌尿外科杂志(电子版), 2024, 18(06): 633-637.
[12] 宋小飞, 巫嘉文, 孙阳. 输尿管开口周围膀胱黏膜预离断联合早期膀胱灌注化疗在上尿路尿路上皮癌根治术中的应用[J/OL]. 中华腔镜泌尿外科杂志(电子版), 2024, 18(05): 479-484.
[13] 吴伟宙, 王琼仁, 詹雄宇, 郑明星, 李亚县. 广东省医学会泌尿外科疑难病例多学科会诊(第16期)——左肾肉瘤样癌[J/OL]. 中华腔镜泌尿外科杂志(电子版), 2024, 18(05): 525-529.
[14] 刘中文, 刘畅, 高洋, 刘东, 林世庆, 杨建华, 赵福义. 尿液microRNA-326与腹腔镜根治性膀胱切除术治疗膀胱癌患者预后的相关性研究[J/OL]. 中华腔镜泌尿外科杂志(电子版), 2024, 18(04): 386-391.
[15] 杨卫东, 周威, 向洪涛. 慢性萎缩性胃炎患者幽门螺杆菌感染与炎性细胞因子及病理特征的关系[J/OL]. 中华消化病与影像杂志(电子版), 2024, 14(05): 459-464.
阅读次数
全文


摘要


AI


AI小编
你好!我是《中华医学电子期刊资源库》AI小编,有什么可以帮您的吗?